MobileODT, a femtech company innovating in cervical screening, has been awarded a prestigious Small Business Innovation Research Authority grant of $2.3 million. This grant is presented by the United States National Cancer Institute (NCI) to leading companies that are technologically and clinically advanced to support the NCI’s goal of reducing suffering and death due to cancer. This grant is a tribute to the…
While cancer therapies are getting more personalized (and expensive), patient outcomes don’t seem to improve along the same trajectory and SynDevRx believes to know why that is. According to the company’s research the answer lies in the way that obesity, diabetes, and other forms of metabolic dysfunction accelerate tumor growth and metastasis, making at least 13 common types of cancer much more…
Pregna has recently announced the launch of its cryotherapy device CryoPop. The product was developed by Jhpiego with an objective of making treatment of cervical pre-cancerous lesions accessible to all. Pregna is the exclusive global commercialising partner for the device. “Cervical cancer is one of the most common and fatal forms of cancer in women worldwide, with about 85% of these deaths occurring in low and…
BioAesthetics Corporation today announced that it has doubled its initial Series A funding goal of $2.5 million, closed on Dec. 30, 2020, at $5 million to commercialize its NACgraft biologic matrix— a regenerative nipple graft for breast cancer survivors. BioAesthetics’ Series A was co-led by FemHealth Ventures and personally by BioAesthetics’ Director Sandra Coufal, MD, of Sibling Capital Ventures. BioAesthetics’ inaugural product, the NACgraft — for patients…
Roche today announced the CE-IVD launch of its automated digital pathology algorithms, uPath HER2 (4B5) image analysis and uPath Dual ISH image analysis for breast cancer to help determine the best treatment strategy for each patient. The image analysis algorithms use artificial intelligence to support pathologists in making faster, more accurate patient diagnoses in breast cancer. The uPath image analysis algorithm suite…
Hologic announced today that it has agreed to acquire Biotheranostics, a privately held, commercial-stage company that provides molecular diagnostic tests for breast and metastatic cancers, for approximately $230 million, subject to working capital and other customary closing adjustments. “Acquiring Biotheranostics enables us to jump-start our entry into a large, fast-growing oncology adjacency that fits perfectly with our broader corporate focus and passion…
Hologic, a medical technology company primarily focused on improving women’s health, announced today it has completed the acquisition of SOMATEX Medical Technologies, a leader in biopsy site markers and localization technologies, for approximately $64 million. The company was previously owned by E-Med Solutions, a group of investors led by German private equity company Westlake Partners. The transaction supports Hologic’s strategy to provide…
Earlier this week Volpara Health announced two new research studies using their AI-powered software to score breast density objectively and consistently to evaluate its impact in mammography and breast cancer risk assessment. Volpara Density software uses a combination of x-ray physics and machine learning to generate an accurate volumetric measure of breast composition and remains the density measurement tool of choice for…
